References
- Lieberman JA: Dopamine partial agonists: a new class of antipsy-chotic. CNS Drugs 2004; 18:251–267
- Physicians Desk Reference 58th Edition (2004): Abilify (aripipra-zole) package insert (revised May 2003), 1034–38
- Burris KB, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al.: Aripiprazole, a novel antipsychotic, is a high-affinity partial ago-nist at human dopamine D2 receptors. Pharmacol and Exp Ther 2002; 302: 381–389
- Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al.: Radioreceptor binding profile of the atypical antip-sychotic olanzapine. Neuropsychopharmacology 1996; 14:87–96
- Stephens DN, Loschmann PA, Lanzinger C, Wachtel H, Montgomery A, Herberg LJ: Unusual interactions between the neuroleptic haloperidol and the dopamine D2 partial agonist, terguride. Behav Pharmacol 1990; 1:521–529